Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win — Live Feedhttps://www.live-feeds.com/feed/amgen-s-horizon-acquired-fusion-protein-eases-sj-gren-s-severity-in-ph-3-winContinuously updated, source-cited coverage. Amgen reports positive Phase 3 results for Sjögren's drug dazodalibephttps://www.live-feeds.com/feed/amgen-s-horizon-acquired-fusion-protein-eases-sj-gren-s-severity-in-ph-3-winhttps://www.live-feeds.com/feed/amgen-s-horizon-acquired-fusion-protein-eases-sj-gren-s-severity-in-ph-3-win#u83119Fri, 25 Sep 2026 00:01:36 +0000Amgen announced positive topline Phase 3 results for dazodalibep, a fusion protein used to treat moderate-to-severe systemic Sjögren's disease. The drug succeeded in its late-stage trial by easing the severity of the autoimmune condition. Following the announcement, Amgen shares rallied 4.3%. The fusion protein was acquired through Amgen's purchase of Horizon.Why it mattersSjögren's disease is a systemic autoimmune condition that often causes dry eyes and mouth. This trial represents a late-stage effort to provide a targeted therapy for patients with moderate-to-severe symptoms.